Author details

Full Name

Christopher Ryan Miller

Affiliation

University of Illinois at Urbana-Champaign

ORCID

Career Start Year

1996

Papers

117

H Index

Expertise

CM4AI Collaborator

Jake Y. Chen (CM4AI)

PMID	Paper Title	Journal Title	Published Year
36927729	Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARÎ³ signaling axis.	Nat Commun	2023
37901180	In-drop thermal cycling of microcrystal assembly for senescence control (MASC) with minimal variation in efficacy.	Adv Funct Mater	2023
37343523	Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.	Cell Rep Med	2023
37068243	Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.	Proc Natl Acad Sci U S A	2023
36865329	Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars.	bioRxiv	2023
36927729	Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARÎ³ signaling axis.	Nat Commun	2023
37901180	In-drop thermal cycling of microcrystal assembly for senescence control (MASC) with minimal variation in efficacy.	Adv Funct Mater	2023
37343523	Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.	Cell Rep Med	2023
37068243	Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.	Proc Natl Acad Sci U S A	2023
36865329	Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars.	bioRxiv	2023
34987156	Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.	Nat Commun	2022
35905726	Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.	Cell Rep	2022
35820706	PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance.	Life Sci Alliance	2022
36006894	Extending the Bioavailability of Hydrophilic Antioxidants for Metal Ion Detoxification via Crystallization with Polysaccharide Dopamine.	ACS Appl Mater Interfaces	2022
35856268	Inter-pathologist agreement on diagnosis, classification and grading of canine glioma.	Vet Comp Oncol	2022
35852875	An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases.	JCI Insight	2022
34987156	Author Correction: Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.	Nat Commun	2022
35856268	Inter-pathologist agreement on diagnosis, classification and grading of canine glioma.	Vet Comp Oncol	2022
35820706	PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance.	Life Sci Alliance	2022
35852875	An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases.	JCI Insight	2022
35905726	Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.	Cell Rep	2022
36006894	Extending the Bioavailability of Hydrophilic Antioxidants for Metal Ion Detoxification via Crystallization with Polysaccharide Dopamine.	ACS Appl Mater Interfaces	2022
34196247	Immunohistochemical evaluation of immune cell infiltration in canine gliomas.	Vet Pathol	2021
34233061	Histatin-1 is an endogenous ligand of the sigma-2 receptor.	FEBS J	2021
34196247	Immunohistochemical evaluation of immune cell infiltration in canine gliomas.	Vet Pathol	2021
34233061	Histatin-1 is an endogenous ligand of the sigma-2 receptor.	FEBS J	2021
32407745	Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.	J Control Release	2020
32407745	Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.	J Control Release	2020
33257985	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.	Neuro Oncol	2020
32642716	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.	Neurooncol Adv	2020
33257985	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.	Neuro Oncol	2020
32642716	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.	Neurooncol Adv	2020
30753579	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.	Neuro Oncol	2019
31788444	Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors.	Front Oncol	2019
30753579	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.	Neuro Oncol	2019
31341075	IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.	J Immunol	2019
31788444	Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors.	Front Oncol	2019
31341075	IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.	J Immunol	2019
28605477	MerTK as a therapeutic target in glioblastoma.	Neuro Oncol	2018
28605477	MerTK as a therapeutic target in glioblastoma.	Neuro Oncol	2018
29016887	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.	Neuro Oncol	2018
29975751	PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.	PLoS One	2018
30239918	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.	J Neuropathol Exp Neurol	2018
29990322	Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.	PLoS One	2018
29938395	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.	Breast Cancer Res Treat	2018
29535300	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.	Nat Commun	2018
29352201	Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.	Sci Rep	2018
29342360	Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.	Mol Pharm	2018
29691296	Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma.	Clin Cancer Res	2018
29409530	Frequency of breast cancer subtypes among African American women in the AMBER consortium.	Breast Cancer Res	2018

1 - 50 of 234

Chirayu Chokshi

McMaster University

Career Start Year 2015

Number of shared co-authors 2

Jason K Sa

Korea University, College of Medicine

Career Start Year 2015

Number of shared co-authors 12

David R Raleigh

University of California san francisco

Career Start Year 2010

Number of shared co-authors 10

Maxim Sidorov

California Pacific Medical Center Research Institute

Career Start Year 2009

Number of shared co-authors 1

Matthew D Wood

Oregon Health & Science University

Career Start Year 2007

Number of shared co-authors 12

Joanna J Phillips

University of California san francisco

Career Start Year 2006

Number of shared co-authors 38

Chitra Venugopal

McMaster Stem Cell and Cancer Research Institute

Career Start Year 2006

Number of shared co-authors 6

Adam M Sonabend

Northwestern University

Career Start Year 2005

Number of shared co-authors 13

Matthias Preusser

Medical University of Vienna

Career Start Year 2003

Number of shared co-authors 19

Gavin P Dunn

Washington University School of Medicine

Career Start Year 2002

Number of shared co-authors 14

Massimo Squatrito

Seve Ballesteros Foundation Brain Tumor group

Career Start Year 2002

Number of shared co-authors 16

Daniel Martinez

Perelman School of Medicine at the University of Pennsylvania

Career Start Year 2002

Number of shared co-authors 8

Sheila K Singh

McMaster University

Career Start Year 2001

Number of shared co-authors 9

Jeongwu Lee

Lerner Research Institute, Cleveland Clinic

Career Start Year 2001

Number of shared co-authors 10

Marta M Alonso

CIMA-Universidad de Navarra

Career Start Year 2001

Number of shared co-authors 26

Brent A Orr

St. Jude Children's Research Hospital

Career Start Year 2000

Number of shared co-authors 20

Ghazaleh Tabatabai

University Hospital Tubingen, Eberhard-Karls-University Tubingen

Career Start Year 1998

Number of shared co-authors 16

Shi-Yuan Cheng

Northwestern University Feinberg School of Medicine

Career Start Year 1996

Number of shared co-authors 9

Do-Hyun Nam

Samsung Medical Center, Sungkyunkwan University School

Career Start Year 1996

Number of shared co-authors 21

Pim J French

Erasmus MC Cancer Institute

Career Start Year 1995

Number of shared co-authors 31

Paul S Mischel

Stanford University

Career Start Year 1994

Number of shared co-authors 29

Charles G Eberhart

Wilmer Eye Institute, Johns Hopkins Medical Institutions

Career Start Year 1993

Number of shared co-authors 42

Jeremy N Rich

UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

Career Start Year 1992

Number of shared co-authors 34

Donald M O'Rourke

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

Career Start Year 1991

Number of shared co-authors 9

Oliver B??gler

American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University

Career Start Year 1990

Number of shared co-authors 15

Howard A Fine

Meyer Cancer Center

Career Start Year 1990

Number of shared co-authors 16

Johan M Kros

Erasmus MC Cancer Institute, University Medical Center Rotterdam

Career Start Year 1988

Number of shared co-authors 30

Motoo Nagane

Kyorin University Faculty of Medicine